Improving Outcomes in Diabetic Retinopathy: A Specialty Pharmacy Discussion of Outcomes and Cost- Effectiveness
0290-0000-18-110-L01-P
1.50
An American Journal of Managed Care Medical Crossfire®: Management of Newer Ultra–Long–Acting Basal Insulin Agents in Diabetes
0290-0000-18-017-H01-P
This Medical Crossfire will highlight the safety and efficacy data related to the newer generation, ultra–long-acting insulins and their place in therapy.
2.00
Evaluating New–Generation Basal Insulin Therapy
0290-0000-18-022-H01-P
This supplement will provide managed care professionals with an overview of diabetes, the status of diabetes control in the U.S., and related comorbidities.
2.50
The Advent of Insulin and GLP–1 RA Fixed–Ratio Agents for Uncontrolled Diabetes: Moving Past the Barriers of Clinical Inertia
0290-0000-18-032-H01-P
At the completion of this activity, the participant will be able to analyze barriers that impact treatment intensification in diabetes.
3.00
Reaching Out® in Diabetes: A Pharmacist's Curriculum to Optimize Insulin Therapy Through Patient Engagement and Management – Patient Cases
0290-0000-17-144-H01-P
With this activity, participants will be able to distinguish starting and titration doses for fixed-dose insulin and GLP-1 RA combination agents.
2.00
Preventing Vision Loss in Diabetic Macular Edema—Role of Specialty Pharmacists
0290-0000-17-132-H01-P
This program aims to identify the impact of rising prevalence in diabetes on diabetic retinopathy, including risk factors, complications, and associated costs.
1.00
Advances in Insulin and Insulin Combination Therapies: Opportunities for Convenient Care Providers to Improve Patient Outcomes
0290-0000-17-138-H01-P
This presentation describes the causes of clinical inertia among patients and health care providers, and reviews the proper use of insulin products.
1.00
Reaching Out® in Diabetes: A Pharmacist's Curriculum to Optimize Insulin Therapy Through Patient Engagement and Management
0290-0000-17-111-H01-P
This activity provides key strategies and case scenarios to optimize patient education and management of diabetes with the GLP-1 RA/ basal insulin combination.
2.00